SCHEMBL12430898

SCHEMBL12430898

Cc1cc(Nc2cc(-c3ccccc3)nc(Oc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 8/20 0.54
AURKA O14965 8/20 0.54
EGFR P00533 4/20 0.53
SRC P12931 2/20 0.52
GSK3B P49841 1/20 0.52
RIPK1 Q13546 5/20 0.51
PLK4 O00444 2/20 0.48
AURKC Q9UQB9 2/20 0.48
BMPR1B O00238 1/20 0.48
STK25 O00506 1/20 0.48
RIOK3 O14730 1/20 0.48
CHEK1 O14757 1/20 0.48
GAK O14976 1/20 0.48
MUSK O15146 1/20 0.48
EPHB6 O15197 1/20 0.48
PDPK1 O15530 1/20 0.48
MAP3K13 O43283 1/20 0.48
DAPK3 O43293 1/20 0.48
MAP3K7 O43318 1/20 0.48
NUAK1 O60285 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430887 0.88 AURKA (0.68) AURKBAURKAEGFRSRCGSK3B
SCHEMBL12430896 0.88 AURKB (0.69) AURKBAURKAEGFRSRCGSK3B
SCHEMBL12430913 0.84 AURKB (0.58) AURKBAURKAEGFRSRCGSK3B
SCHEMBL12430807 0.82 AURKB (0.79) AURKBAURKAEGFRSRCGSK3B
SCHEMBL12510643 0.81 AURKB (0.58) AURKBAURKAEGFRSRCGSK3B
SCHEMBL12430901 0.80 AURKA (0.57) AURKBAURKAEGFRSRCGSK3B
SCHEMBL12430905 0.80 AURKB (0.57) AURKBAURKAEGFRGSK3BTNIK
SCHEMBL12430899 0.79 AURKB (0.49) AURKBAURKAEGFRSRCGSK3B
SCHEMBL12430890 0.79 AURKA (0.51) AURKBAURKAEGFRSRCGSK3B
SCHEMBL12430897 0.77 AURKB (0.47) AURKBAURKAEGFRSRCGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA AURKB 7/4885AURKA 3/4885EGFR 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.